Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | RAD52 | P43351 | 1/20 | 0.45 |
| ▸ | CXCR4 | P61073 | 7/20 | 0.44 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | ANPEP | P15144 | 2/20 | 0.41 |
| ▸ | ERAP2 | Q6P179 | 2/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.40 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.40 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23016010 | 1.00 | KDM4E (0.46) | KDM4ERAD52CXCR4CXCL12ALDH1A1 | |
| SCHEMBL1913633 | 1.00 | KDM4E (0.46) | KDM4ERAD52CXCR4CXCL12ALDH1A1 | |
| SCHEMBL5700126 | 1.00 | KDM4E (0.46) | KDM4ERAD52CXCR4CXCL12ALDH1A1 | |
| SCHEMBL24029510 | 1.00 | KDM4E (0.46) | KDM4ERAD52CXCR4CXCL12ALDH1A1 | |
| SCHEMBL197742 | 1.00 | KDM4E (0.46) | KDM4ERAD52CXCR4CXCL12ALDH1A1 | |
| Hydrochloric Acid SCHEMBL11553329 | 0.97 | KDM4E (0.44) | KDM4ERAD52CXCR4CXCL12ALDH1A1 | |
| SCHEMBL8489099 | 0.97 | — | — | |
| SCHEMBL10064482 | 0.92 | — | — | |
| Hydrochloric Acid SCHEMBL31720531 | 0.89 | — | — | |
| SCHEMBL17710326 | 0.89 | CA12 (0.48) | KDM4ERAD52CXCR4CXCL12ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170128489-A1 | ORGANO-TRANSITION METAL COMPLEXES FOR THE TREATMENT OF VIRAL INFECTIONS | BRIGHAM YOUNG UNIVERSITY (US) | 2017-05-11 | — | — | US | disclosed |
| US-20170128489-A1 | ORGANO-TRANSITION METAL COMPLEXES FOR THE TREATMENT OF VIRAL INFECTIONS | BRIGHAM YOUNG UNIVERSITY (US) | 2017-05-11 | — | — | US | disclosed |
| US-20170128489-A1 | ORGANO-TRANSITION METAL COMPLEXES FOR THE TREATMENT OF VIRAL INFECTIONS | BRIGHAM YOUNG UNIVERSITY (US) | 2017-05-11 | — | — | US | disclosed |
| WO-2015192037-A1 | ORGANO-TRANSITION METAL COMPLEXES FOR THE TREATMENT OF VIRAL INFECTIONS | BUSATH DAVID D (US) | 2015-12-17 | — | — | WO | disclosed |
| WO-2015192037-A1 | ORGANO-TRANSITION METAL COMPLEXES FOR THE TREATMENT OF VIRAL INFECTIONS | BUSATH DAVID D (US) | 2015-12-17 | — | — | WO | disclosed |
| US-7544794-B1 | Method for sequencing DNA and RNA by synthesis | BENNER STEVEN ALBERT | 2009-06-09 | — | — | US | disclosed |
| WO-2007005896-A2 | ANTI-TUBERCULAR DRUGS: COMPOSITIONS AND METHODS | SEQUELLA, INC. (US) | 2007-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170128489-A1 | ORGANO-TRANSITION METAL COMPLEXES FOR THE TREATMENT OF VIRAL INFECTIONS | HVCN1, TRPM8, TRPM2 | KDM4E 3591/4885RAD52 3414/4885CXCR4 3300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.